Current use of PSMA–PET in prostate cancer management

  title={Current use of PSMA–PET in prostate cancer management},
  author={Tobias Maurer and Matthias Eiber and Markus Schwaiger and J{\"u}rgen Gschwend},
  journal={Nature Reviews Urology},
Currently, the findings of imaging procedures used for detection or staging of prostate cancer depend on morphology of lymph nodes or bone metabolism and do not always meet diagnostic needs. Prostate-specific membrane antigen (PSMA), a transmembrane protein that has considerable overexpression on most prostate cancer cells, has gained increasing interest as a target molecule for imaging. To date, several small compounds for labelling PSMA have been developed and are currently being investigated… 

Prostate-specific membrane antigen in prostate cancer imaging and treatment

  • E. Lim
  • Medicine, Biology
    Translational Cancer Research
  • 2018
While PSMA-PET appears superior to conventional imaging, it also has limitations with sensitivity in certain settings and well-designed prospective clinical trials should be conducted in order to understand the true potential of this novel imaging modality.

Clinical perspectives of PSMA PET/MRI for prostate cancer

The potential role of PSMA PET/MRI for the clinical assessment of PCa is outlined and interesting applications for tumor detection, primary staging, assessment of therapeutic responses and treatment planning are shown.

The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer

The authors discuss the current evidence for the use of prostate-specific membrane antigen (PSMA) PET and whole-body (WB) MRI, consider the evolving use of PSMA PET-derived and WB MRI-derived quantitative biomarkers and make recommendations for future clinical trials of these modalities.

Impact of the 68Ga Prostate-Specific Membrane Antigen (68Ga-PSMA) PET/CT on the Management of Prostate Cancer

The efficiency and sensitivity of 68Ga-labelled prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomographic (CT) imaging in comparison to other radiotracers and imaging techniques are discussed.

Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy

PSMA-targeted tracers have shown unprecedented accuracy to stage and restage PCa using PET/CT, and are potentially offering a new line of targeted therapy for metastatic castration-resistant PCa.

PSMA PET and Radionuclide Therapy in Prostate Cancer.

The "image and treat" strategy, with radiolabeled PSMA ligands, has the potential to improve the treatment outcome of patients with PCa and is paving the way for precision medicine in PCa.

Prostate Cancer-Specific Positron Emission Tomography with Different Radiotracers.

Recent advances of current state of PET radiotracers for potential use in the imaging evaluation of prostate cancer are reviewed, with the intention of providing a high-yield primer for urologists managing patients with prostate cancer.

New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography

Gallium-68-labelled PSMA PET has increased the sensitivity of detection of disease recurrence at low PSA levels, thus allowing an optimal window for salvage treatment and has the potential for increasing sensitivity and specificity for primary tumour localisation and in detecting lymph node disease.



68Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer

This work presents an exemplarily case of primary staging using multiparametric 68Ga-PSMA PET/MR by combining molecular and structural information and suggests the combination of excellent morphological detail, multiparametry functional information, and molecular PET data might lead to a significant improvement in detection of prostate cancer.

PET imaging in prostate cancer: focus on prostate-specific membrane antigen.

Early clinical results suggest that PET/CT using PSMA-targeted agents, especially with compounds of low molecular weight, will make valuable contributions to the management of PCa.

Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations

  • H. Jadvar
  • Medicine, Biology
    European Journal of Nuclear Medicine and Molecular Imaging
  • 2013
Cumulative current evidence suggests that FDG PET may be useful in detection of disease in a small fraction of patients with biochemical recurrence, in the imaging evaluation of extent and treatment response in metastatic disease and in prediction of patient outcome.

Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature.

Positron emission tomography (PET) with a number of tracers targeted to particular biological features of cancer has been explored for the imaging evaluation of patients with biochemical recurrence

PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions

The biodistribution of the novel 68Ga-PSMA tracer and its ability to detect PC lesions was analysed in 37 patients to suggest that this novel tracer can detect PC relapses and metastases with high contrast.

18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer

The utility of PSMA-based PET, which may be used in conjunction with MR imaging to identify clinically significant prostate cancer, is demonstrated.

The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions

The aims of this evaluation were to clinically investigate the distribution of 68Ga-PSMA-617 in normal tissues and in PCa lesions as well as to evaluate the radiation exposure by the radioligand in PET imaging.

Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT

PSMA-based PET/CT with radiotracers such as 18F-DCFPyL may allow more accurate staging of patients with RCC and conceivably the ability to predict and follow therapy in patients treated with agents targeting the neovasculature.